Dynavax and AstraZeneca agree to conduct toxicology studies for TLR-9 agonist for asthma

Wednesday, 21 December 2011

Dynavax Technologies Corporation announced today they will advance AZD1419, a proprietary second-generation TLR-9 agonist for asthma, into IND-enabling preclinical toxicology studies. These toxicology studies are scheduled to be the first module of work performed by Dynavax under the recently amended collaboration agreement with AstraZeneca for the clinical development of AZD 1419. Development expenses will be fully funded by AstraZeneca, and Dynavax will receive payment of $2.6 million to begin the studies.

View full press release

Download our brochure

Download your comprehensive guide to partnering with us.

Meet us at an event

Calendar iconView our full event calendar to see events we are attending.

View calendar